ArticleDiscover oncology2025
Causal plasma metabolites for breast cancer risk: a two-sample Mendelian randomization study with colocalization evidence.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast cancer pathogenesis involves complex metabolic dysregulation, yet causal biomarkers remain elusive. This study aimed to assess causal effects of 1,400 human plasma metabolites on breast cancer (BC) risk using a two-sample Mendelian randomization (MR) framework.
methodsWe employed a rigorous two-sample Mendelian randomization framework with tiered quality control (Bonferroni correction, sensitivity analyses, meta-analyses) to investigate causal metabolite-BC associations. Colocalization (PPH4 > 0.80) and phenome-wide MR (2,099 FinnGen phenotypes) validated mechanistic specificity and clinical safety profiles.
resultsFive genetically determined plasma metabolites were identified as the potential causal biomarkers for BC risk: 3,5-dichloro-2,6-dihydroxybenzoic acid (odds ratio [OR]: 0.90; 95% confidence interval [CI] 0.87-0.94; p < 0.001), carnitine C14 (OR: 0.72; 95% CI 0.64-0.83; p < 0.001) and epiandrosterone sulfate (OR: 1.04; 95% CI 1.01-1.06; p < 0.001), Glyco-beta-muricholate (OR: 0.95; 95% CI 0.93-0.97; p < 0.001), N4-acetylcytidine (OR: 0.93; 95% CI 0.91-0.96; p < 0.001). Colocalization analysis showed strong evidence for Glyco - beta - muricholate and Epiandrosterone sulfate with BC risk (PPH4 = 1). PheWAS-MR revealed metabolite-specific safety profiles, with carnitine C14 showing broadest phenotypic associations (96 outcomes).
conclusionsThis study establishes carnitine C14 as a novel protective biomarker and epiandrosterone sulfate as a risk biomarker for breast cancer, with colocalization evidence supporting their therapeutic targeting. The metabolic risk profile provides a foundation for precision prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.